Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!

Analyst: Insulet On Track For Profitability In 2018

Courtesy of Benzinga.

Analyst: Insulet On Track For Profitability In 2018

Insulet Corporation (NASDAQ: PODD) is up 80.5 percent year-over-year, and even last quarter’s bottom-line miss can’t deter the biotech’s bulls.

The Rating

BMO Capital Markets analyst Joanne Wuensch initiated coverage of Insulet Corp. with an Outperform rating and $90 price target.

The Thesis

Wuensch anticipates a turn to profitability in the second half of 2018, with a series of catalysts sustaining positive performance.

Over the next two years, Insulet is expected to profit from the rollout of the OmniPod Dash platform and Horizon Automated Glucose Control System; a push for international direct sales; penetration of the U.S. Medicare market; approved distribution of higher concentration insulin; and expansion in Type 2 diabetes, the analyst said. 

At the same time, its Omnipod product is positioned to expand in an “underpenetrated” insulin pump market and capture the share abandoned by Roche and Johnson & Johnson (NYSE: JNJ), Wuensch said. The analyst said she expects a three-year share expansion from 15.2 percent to 22.1 percent.

“Insulet is on the right side of care with its OmniPod Pump, providing an easier, more efficacious means of insulin delivery without the obstacles of traditional pumps or multiple daily injections,” she said in a Monday note. 

Price Action

Insulet shares were up 2.31 percent at $77.57 in midday trading Tuesday. 

Related Links:

7 Biotech Stocks With Clinical Trial Outcomes In March

Pharma M&A Picks Up Momentum

Latest Ratings for PODD

Date Firm Action From To
Mar 2018 BMO Capital Initiates Coverage On Outperform
Feb 2018 Barclays Maintains Overweight Overweight
Feb 2018 Cowen & Co. Maintains Outperform Outperform

View More Analyst Ratings for PODD


View the Latest Analyst Ratings

Posted-In: BMO Capital Markets Joanne WuenschAnalyst Color Biotech Price Target Initiation Analyst Ratings General Best of Benzinga


Do you know someone who would benefit from this information? We can send your friend a strictly confidential, one-time email telling them about this information. Your privacy and your friend's privacy is your business... no spam! Click here and tell a friend!





You must be logged in to make a comment.
You can sign up for a membership or get a FREE Daily News membership or log in

Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!